End points in clinical trials: Are they moving the goalposts?

Heart

Volumn 92, Issue 7, 2006, Pages 870-872

  Leung, D Y ^a   French, John K ^a  

^a LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB;

BLEEDING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; EDITORIAL; EVALUATION; HEALTH CARE; HEART MUSCLE NECROSIS; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; METHODOLOGY; MORTALITY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; CORONARY ARTERY BYPASS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; SAFETY MANAGEMENT; TREATMENT OUTCOME;

EID: 33745652295     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.082024     Document Type: Editorial

References (10)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
2. French JK, White HD. Clinical implications of the new definition of myocardial infarction. Heart 2004;90:99-106.
3. Sedgwick JEC. Absolute, attributable, and relative risk in the management of coronary heart disease. Heart 2001;85:491-2.
4. Roe MT, Mahaffey KW, Kilaru R, et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J 2004;25:313-21.
5. Akkerhuis KM, Alexander JH, Tardiff BE, et al. Are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6.
6. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
7. Chew DP, Bhatt DL, Lincoff AM, et al. Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart 2006;92:945-50.
8. Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001;104:2689-93.
9. Klatte K, Chaitman BR, Theroux P, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol 2001;38:1070-7.
10. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina. Lancet 2002;360:743-51.